Implementation of Community Health Worker Support for Tobacco Cessation: A Mixed-Methods Study

Cheryl Y. S. Foo, Ph.D.[1,2], Kevin Potter, Ph.D.[1,2], Lindsay Nielsen, B.A.[1], Aarushi Rohila, B.A.[1], Melissa Culhane Maravic, Ph.D.[1], Kristina Schnitzer, M.D.[1], Gladys N. Pachas, M.D.[1,2], Douglas E. Levy, Ph.D. [2,3], Sally Reyering, M.D.[4], Anne N. Thorndike, M.D.*[2,5], Corinne Cather, Ph.D.* [1,2], A. Eden Evins, M.D.* [1,2]

* *Contributed equally as senior authors*

Author institutional affiliations: [1] Massachusetts General Hospital, Department of Psychiatry; [2] Harvard Medical School; [3] Massachusetts General Hospital, Mongan Institute; [4] Bay Cove Human Services; [5] Massachusetts General Hospital, Division of General Internal Medicine.

Correspondence to: Cheryl Y. S. Foo, cfoo1@mgh.harvard.edu, Massachusetts General Hospital Center of Excellence for Psychosocial and Systemic Research, One Bowdoin Square, Suite 905, Boston, MA 02114; Phone: (617)-724-0163

Disclosures: Dr. Evins has served as a consultant to Charles River Analytics (NIDA SBIR grant) and was supported in part by NIH grant K24 DA030443 and PCORI 1504-30472. Dr. Cather has served as a consultant to Charles River Analytics (NIDA SBIR grant). Other investigators report no potential conflicts.

Funding: This work was funded by the Patient Centered Outcomes Research Institute (PCORI) Large Pragmatic Trial, 1504-30472; Integrated Smoking Cessation Treatment for Smokers with Serious Mental Illnesses (PI: Evins; co-PI; Reyering); ClinicalTrials.gov identifier, NCT02845440. Dr. Thorndike was supported in part by NIH grant K24 HL163073. Dr. Foo was supported by funding from the Massachusetts Department of Mental Health to the

Massachusetts General Hospital Center of Excellence for Psychosocial and Systemic Research.

Acknowledgements: The authors thank all participants and staff involved in the trial; Michael D. Fetters, for his expert guidance on conceptualization of the mixed methods design; and Diana Arntz, for supporting qualitative data collection.

Data Sharing Statement: The complete de-identified dataset of individual-participant level data that underpin the results reported in this article, together with the full study protocol, statistical analysis plan and statistical code used to generate the results will be archived, searchable, and open access, posted through the PCORI Patient-Centered Outcomes Data Repository, hosted by the University of Michigan's Inter-University Consortium for Political and Social Research (ICPSR. ICPSR is an open access repository that connects researchers to data funded by PCORI. According to PCORI's policy, the data requestor will enter a DUA and submit a request outlining their research purpose directly with the data repository. Their qualifications, research justification, data security plan, and assurance that the research will result in a generalizable, patient-relevant contribution will all be taken into account by a PCORI-designated review committee. Such requests and derived results are posted publicly. The DUA prohibits reidentification.

Previous presentations: Parts of this study have been presented at the Massachusetts General Hospital Annual Public and Community Psychiatry Symposium on March 15, 2023, and at the Massachusetts General Hospital Clinical Research Day on October 12, 2023.

ABSTRACT

Objective: Adults with serious mental illness (SMI) have high tobacco use disorder (TUD) rates and underutilization of first-line TUD pharmacotherapy. In a randomized trial, a community health worker (CHW) plus primary care provider (PCP) education (PE) intervention improved tobacco abstinence in this population at two years, partly through increasing TUD pharmacotherapy initiation. The current study determined how engagement between participants and CHWs was associated with these outcomes.

Methods: This was a secondary, mixed-methods analysis of 196 participants in the PE+CHW arm of the RCT. Effects of CHW visit number and duration (minutes), CHW co-led smoking cessation group sessions attended, and CHW-attended PCP visit number on TUD pharmacotherapy initiation and tobacco abstinence were modeled using logistic regression. Interviews with 12 CHWs, 16 participants, and 17 PCPs were analyzed thematically.

Results*:* Year-two tobacco abstinence was associated with one SD increases of CHW visit number (OR=1.85, [1.29, 2.66]) and duration (OR=1.85 [1.33, 2.58]) and number of groups attended (OR=1.51 [1.00, 2.28]); effects on TUD pharmacotherapy initiation were similar. 1-3 CHW visits per month over two years was optimal for achieving abstinence. Interviews identified engagement facilitators, including CHWs providing goal accountability, skills reinforcement and assistance overcoming barriers to treatment access and adherence. Robust training and supervision facilitated CHW effectiveness. Barriers included PCPs' and care teams' limited understanding of the CHW role.

Conclusions: Greater CHW engagement within feasible dose ranges was associated with increased tobacco abstinence in adults with SMI. Implementation of CHW interventions may benefit from promoting CHW training and integration within clinical teams.

INTRODUCTION

Tobacco smoking is a major contributor to premature mortality in individuals with serious mental illness (SMI) [1]. Higher rates of tobacco use disorder (TUD) and tobacco-related illness [2,3], drives a 25-year mortality gap compared to those without mental illness [4]. TUD pharmacotherapies, particularly varenicline, are effective and safe for those with SMI [5–7], but underutilized [2,8,9], due to provider knowledge gaps [10,11] and low prioritization of TUD treatment in psychiatric care [12]. Further, those with SMI have lower TUD treatment adherence [13], attributable to illness-related symptoms and cognitive impairment and to adverse social determinants of health that create barriers to treatment access and adherence [14]. Given these multi-level barriers [15], innovations are imperative to promote initiation and adherence to first-line TUD healthcare to reduce TUD-related morbidity and mortality for people with SMI.

Community health workers (CHWs) are frontline public health workers who can bridge treatment gaps for marginalized populations by providing care coordination and assistance with treatment uptake and adherence [16] through health education, advocacy, coaching/counseling, case management, and addressing health-related social needs [17]. CHWs improve hypertension, diabetes, and HIV/AIDS outcomes [18]. In a recent pragmatic clinical trial [19], we demonstrated that CHW support both to adults with SMI and TUD and also their primary care physicians (PCPs) for two years, combined with provider education (PE) on evidence-based TUD treatment in people with SMI, increased bio-verified tobacco abstinence rates over usual care or PE alone, in part through increased varenicline initiation. There was also an independent effect of the CHW; participants who received TUD pharmacotherapy with CHW support were three-fold more likely to quit smoking than those receiving TUD pharmacotherapy without CHW support [19]. To guide future implementation efforts, we undertook a secondary analysis of this study to identify effective dose ranges and critical components of the CHW intervention [20] and identify barriers and facilitators of implementing the CHW intervention.

METHODS

Study Design. This study utilized a parallel mixed-methods design to determine effective type (one-to-one CHW visits, CHW co-led smoking cessation groups, CHW-accompanied PCP visits) and dose (number, duration) of participant-CHW engagement. To identify barriers and facilitators to implementing the CHW intervention, we conducted post-intervention interviews with stakeholders participating in the PE+CHW arm. The study was approved by Massachusetts General Hospital and Massachusetts Department of Mental Health institutional review boards.

CHW Intervention. In the parent trial (11/2017 to 01/2020) [19], primary care clinics were cluster-randomized to PE or usual care; PE-assigned clinics had a nested, participant-level randomization to CHW or no CHW. Participants did not need to express willingness to quit smoking to enroll. The content and delivery of the CHW intervention was flexible, and largely determined by individual participant characteristics and preferences. CHWs were twelve bachelor's-level staff without clinical training or tobacco cessation experience who completed a two-week training covering core competencies for CHW certification [21], agency-mandated safety training, Tobacco Treatment Specialist Core Training [22], skills to facilitate illness self-management, and education about the safety and efficacy of first-line TUD pharmacotherapies. CHWs visited participants in their homes or neighborhoods, co-led community-based smoking cessation group counselling sessions with a clinically-trained study staff member, encouraged participants to discuss their tobacco use, set smoking cessation goals, educated participants about safety and efficacy of TUD medications, assisted participants at PCP visits and smoking cessation groups, aided communication with PCPs and community support staff, and addressed participants' unmet social determinants of health [19]. CHWs received weekly clinical group supervision and as-needed individual supervision, and charted participant encounters.

Quantitative Method

Participants. Of 336 adults with TUD and SMI eligible for state psychiatric rehabilitation services assigned to the PE+CHW arm of the RCT, 116 (35%) did not consent to CHW support, and 21 (6%) consented participants dropped out before the Year 1 assessment. 196 retained participants were included in the analysis after excluding data from three outliers with ≥120 CHW visits (average SD above mean=4.2).

Data Collection and Measures. Data on participants' engagement with CHWs were extracted from CHW-reported weekly progress notes, consisting of each participant's number and duration of in-person CHW visits, number of smoking cessation groups attended, and number of CHW-attended PCP visits and converted to z-scores for regression analyses. Outcomes were assessed blindly at Years 1 and 2 and included whether participants reported taking ≥1 dose of any TUD pharmacotherapy (nicotine replacement therapy, bupropion, varenicline), taking ≥1 dose of varenicline specifically, and whether participants achieved 7-day point prevalence abstinence (self-report of no prior week tobacco smoking and expired carbon monoxide (CO) of ≤5 parts per million [23]).

Statistical Analysis. We tested linear and quadratic relationships between each CHW engagement dose parameter, converted to a z-score, and each outcome using logistic regression models. Missing data for Year 2 tobacco abstinence in 43 participants were imputed ten times via predictive mean matching using Year 1 abstinence outcomes and baseline characteristics, as in the parent study [19]. To identify effective doses of the CHW intervention components, we calculated the minimum threshold associated with significant improvement (i.e., expected response on outcome exceeds the 95% prediction interval for the response given no intervention), and then calculated the maximum threshold with no further significant improvement (i.e., expected response falls below the 95% prediction interval for the highest

possible predicted response) [24]. Analyses were conducted using R [25] with missing data imputed using the 'mice' package [26].

Qualitative Method

Participants. All 12 CHWs were interviewed. Study participants randomized to CHW support who completed the two-year intervention (N=153) were eligible for interview. All PCPs who received PE (N=111) were contacted for interview. Participant interviewees were selected using purposive sampling to represent a range of TUD treatment outcomes achieved (tobacco cessation, TUD pharmacotherapy initiated, percentage of behavioral smoking goals achieved in CHW sessions). Participants were interviewed until thematic saturation was reached. PCPs interviewed were a convenience sample based on interest in participating. Interviewees provided written informed consent and were compensated $15 for participation.

Interview Procedure. Semi-structured, individual interviews were conducted post-intervention to capture stakeholders' experiences, attitudes, and perceived barriers and facilitators to effective engagement and implementation of the CHW intervention. Interviews were conducted in English in-person, via telephone, or videoconference (MCM, KS, DA), audio-recorded and transcribed verbatim, except in the case of one participant who refused audio-recording for which detailed notes were used.

Qualitative Analysis. Team members (CF, LN, AR) independently coded transcribed interviews. We analyzed transcripts from each stakeholder group separately using a coding reliability approach to thematic analysis [27], first applying an *a priori*, deductive coding frame of higher-order domains based on the Consolidated Framework for Implementation Research (CFIR) [28], a framework designed to identify multilevel barriers and facilitators at the systemic, organizational, user, and intervention levels. Next, team members inductively identified themes that were confirmed by team discussion and consensus then mapped onto CFIR constructs [29]. Intercoder reliability was implemented in up to 25% of interviews from each stakeholder

group until satisfactory reliability (κ ≥ 0.75) was achieved [30,31]. Coding differences and codebook refinements were resolved after each round of coding to ensure themes were comprehensively and accurately captured across all transcripts. We reviewed and synthesized all codes across stakeholder groups to identify major salient themes with consideration of lesser endorsed codes that were relevant and important to informing future implementation of the CHW intervention. Qualitative analysis was managed using NVivo 12 for Mac [32]. See Online Supplement 1 for detailed analytic method.

RESULTS

Quantitative Results

Dose effects of CHW engagement. 196 participants (30% female; 1% American Indian or Alaskan Native; 2% Asian; 39% Black or African American; 17% Hispanic/Latinx; 3% multiracial; 37% white; 51% living in supervised housing; moderate nicotine dependence on Heaviness of Smoking Index [33]; mean age: 49-years-old) were included in the analysis (see Online Supplement 2 for detailed participant characteristics by enrollment and retention). Higher number and longer duration of CHW visits and more group visits attended were generally associated with higher likelihood of smoking cessation and TUD pharmacotherapy initiation (Figure 1). For tobacco abstinence, there were significant dose effects given a standard deviation unit increase in CHW visit number (OR=1.85, z-score [1.29, 2.66]; SD=28 visits), CHW visit duration (OR=1.85 [1.33, 2.58]; SD=14 minutes), and number of smoking cessation groups attended (OR=1.51 [1.00, 2.28]; SD=23 sessions) (Table 1). Dose effects for TUD pharmacotherapy initiation were slightly larger and included a significant effect from CHW-attended PCP visit number (OR=5.64 [2.67, 11.91]; SD=3 visits).

The optimal dosage ranges of CHW support for Year 2 tobacco abstinence were 30 to 65 visits over two years (e.g., 1-3 visits per month), 29 to 34 minutes per visit (e.g., half-hour visits), and 20 to 57 CHW co-led smoking cessation groups (e.g., 1-3 groups per month) (Table

1). Increasing the dose of CHW engagement above these levels led to only marginal outcome improvements. For CHW visits, visit duration, and cessation groups, 36%, 47%, and 26% of participants, respectively, received this minimum threshold of dose for tobacco abstinence.

Qualitative Results

Twelve CHWs (83% female; 75% White; mean age: 27-years-old), 16 participants (Table 2) and 17 PCPs (47% female) were interviewed. Generally, interviewees across all groups valued all types of CHW intervention (CHW visits, smoking cessation groups, and CHW-attended PCP visits) and perceived them to be integral to participants' tobacco reduction or cessation. Factors influencing implementation of PE and smoking cessation groups are reported in Online Supplement 3.

We focus on five major barriers and facilitators to effective participant engagement and implementation of the CHW intervention, presented in Table 3 along with their corresponding CFIR domains, illustrative quotes, and recommendations for implementation. These factors are categorized into three major themes: (1) CHW strategies that facilitated TUD treatment engagement and smoking behavior change; (2) care coordination challenges with PCPs and other providers; and (3) importance of CHW training and supervision.

CHW role in facilitating TUD treatment engagement and behavioral change. CHWs stressed the importance of alliance building with participants, especially by focusing on general health goals for those not ready to quit smoking. CHWs and participants reported several key strategies that CHWs used to facilitate goal accountability, including providing education on evidence-based smoking cessation practices, using motivational interviewing, and reinforcing health behavior change by assisting participants to practice skills learned from groups (e.g., identifying triggers and implementing coping skills) in their neighborhoods. Using CO monitoring during CHW visits helped quantify participants' progress towards tobacco cessation, which was reported to facilitate CHWs' ability to reinforce participant progress and problem-solve obstacles

to meeting smoking cessation goals, and thus enhance both participant engagement and the CHW's sense of competence.

Notably, all stakeholder groups highlighted how CHWs facilitated participant engagement by helping participants overcome barriers to TUD treatment access and adherence. CHWs addressed adverse social determinants of health and mitigated the impact of cognitive and motivational deficits associated with SMI and shortfalls in health literacy (e.g., reducing transportation barriers by meeting participants in their homes/neighborhood, scheduling and organizing transportation to PCP appointments and groups, navigating insurance lapses for maintenance of TUD pharmacotherapy, collaborating to devise workable medication adherence regimens and reminders).

Care coordination challenges with primary care and other providers. Most interviewees reported positive experiences of CHWs assisting participants in advocating for their health goals with PCPs, obtaining prescriptions for TUD pharmacotherapy, and liaising with participants' psychiatric rehabilitation teams to support medication adherence. However, some CHWs encountered resistance from PCPs with respect to their role on the participants' care teams, describing instances where their input on cessation medication use was dismissed. A few PCPs expressed concerns about CHWs potentially undermining their clinical authority and decisions.

CHWs also had mixed experiences coordinating care with other psychiatric rehabilitation providers. For example, some CHWs reported that residential staff had little understanding of the CHW role, had conflicting approaches to smoking cessation (e.g., using punitive measures, or providing cigarettes as a reward), and were unresponsive to care coordination efforts.

Importance of CHW training and supervision. Nearly all CHWs spoke positively about pre-intervention specialized training and ongoing clinical supervision, which helped them handle challenging clinical situations and develop their competency. Many found value in the

apprenticeship learning model, where they shadowed clinical outreach teams before taking on cases. CHWs encountered some unanticipated challenges and made suggestions to improve future trainings to prepare them to work more effectively in community settings with individuals with SMI, particularly those from differing cultural backgrounds.

DISCUSSION

Greater engagement between participants and CHWs was associated with higher tobacco abstinence rates in adults with SMI. Significantly increased smoking abstinence rates were observed with highly feasible CHW intervention dose ranges of one to three 30-minute CHW visits and one to three CHW co-led smoking cessation groups per month over two years. These doses were received by over a quarter of participants. Qualitative findings from study participants, CHWs, and PCPs identified factors influencing successful CHW intervention implementation, and specific CHW critical functions that helped overcome participants' barriers to TUD treatment uptake and adherence in a primary care context.

Ideally, implementation of an evidence-based CHW intervention must strike a balance between the maximally efficacious dose and the dose that is reasonably affordable and feasibly accepted by a large enough proportion of recipients to be beneficial in real-world settings. As TUD is a chronic condition and study participants were not necessarily interested in quitting smoking at enrollment, it was not surprising that an extended duration intervention was associated with better TUD outcomes [34,35]. In an 18-month tobacco cessation and weight management intervention for people with SMI, abstinence rates increased over time, particularly for those who were not willing to try to quit smoking immediately. The greatest increase in abstinence occurred after one year in this group [36], replicating prior work with people with major depressive disorder who smoked [37]. Central to our approach was an opt-out approach recommending TUD pharmacotherapy initiation in all who smoke [38] now incorporated in clinical best practices [39]. We suspect TUD pharmacotherapy use was important for enhancing

motivation and self-efficacy for cessation via reducing craving and enjoyment of tobacco smoking. CHW interviews suggested that consistent engagement over time in participants' homes and communities was essential for building trust with participants, particularly those not initially interested in quitting, by engaging and motivating participants first through discussing general health goals and providing practical assistance in addressing barriers related to social determinants of health. Further research can explore different dosing schedules for initiation and maintenance of smoking cessation behaviors and cost-effectiveness of the CHW intervention. Future implementation may also explore CHW extension through telehealth [40], mobile apps [41], and group formats to promote scalability of the CHW TUD intervention.

Another key finding was the identification of CHW-attended PCP visits as a high-yield strategy for increasing initiation of TUD pharmacotherapy. Nearly half of participants who had a single CHW-attended PCP visit used a TUD pharmacotherapy, and almost 25% used varenicline. This is an important outcome given the recently reported persistent low prescribing rates of nicotine replacement therapy (1.6%) and varenicline (2.4%) for individuals with SMI and TUD [8]. Qualitative findings highlighted CHWs' critical role in overcoming barriers to physician prescribing by addressing transportation challenges to PCP visits; advocating for participants and reinforcing provider education about TUD pharmacotherapy during PCP visits; serving as a communication liaison with PCPs around any adverse effects of treatment, navigating insurance lapses that affected prescription access; and communicating with participants' psychiatric rehabilitation team to support medication adherence.

Concordant with prior trials demonstrating CHW efficacy in providing coaching to improve health behaviors impacting chronic health conditions in primary care settings [42,43], qualitative results highlighted that CHWs also extended the benefits of skills-based smoking cessation groups and TUD pharmacotherapy in this study. CHWs further facilitated treatment engagement by overcoming barriers often experienced by people with SMI [14,15,44],

particularly via addressing participants' adverse social determinants of health, disease-related factors, cultural and linguistic barriers, and helping to navigate complex health systems.

Finally, multiple stakeholders emphasized the need for thoughtful integration of the CHW role within the healthcare system, such as a health-focused psychiatric rehabilitation worker who can support illness management across different care settings for people with SMI. This finding is consistent with studies highlighting that poor coordination and collaboration of CHWs with other healthcare providers may compromise sustained implementation of CHW interventions [45,46]. More education and awareness-raising about CHW effectiveness, which could be propelled by recent calls for CHW professionalization [16,17] and recognition of their contributions to equitable provision of evidence-based care (e.g., in the Affordable Care Act, [47,48]), complemented with robust training and supervision, could support smoking cessation in people with SMI and potentially other mental health conditions in community care settings.

Limitations

Secondary analysis of participants from the intervention arm of a clinical trial may limit generalizability to other contexts, such as non-SMI populations, those not connected to primary care, and rural settings. Our dose-response analyses were based on observed doses conditional on participants' acceptance of the intervention; a future trial with a fixed target dose would be needed to definitively determine efficacious dosage. Dosing parameters may also be confounded with intervention content (e.g., longer sessions may incorporate more skills) [49], although we can assume fidelity to intervention due to the robust CHW training and supervisory structure within the trial. We ensured trustworthiness of qualitative results by using reliable coding techniques, illustrative quotes, and external audit. However, PCP and patient participants who self-selected to interview were likely to be more engaged in the study. Additionally, perspectives from disengaged or non-consenting participants, and administrator and policy-

maker insights into system-level constraints and facilitators (e.g., capacity, budget) were not obtained.

CONCLUSIONS

Greater participant engagement with CHWs within feasible dose ranges were important for achieving better tobacco cessation outcomes in adults with SMI and TUD. Integrating CHWs into psychiatric rehabilitation teams and recognizing their role as behavioral health coaches, patient advocates, and care coordinators were perceived as important for successful implementation. Future research optimizing scalable delivery formats and cost-effectiveness for CHW intervention components can enhance effectiveness and implementation of CHW-supported tobacco cessation in psychiatric rehabilitation and primary care teams. There is potential to extend this effective behavioral health care model to other health needs of those with SMI and to other high-need populations facing treatment barriers related to social determinants of health.

References

1. Olfson M, Gerhard T, Huang C, et al:. Premature Mortality Among Adults With Schizophrenia in the United States. JAMA Psychiatry. 2015 Dec;72(12):1172–81.

2. Han B, Aung TW, Volkow ND, et al: Tobacco Use, Nicotine Dependence, and Cessation Methods in US Adults With Psychosis. JAMA Network Open. 2023 Mar 28;6(3):e234995.

3. McClave AK, McKnight-Eily LR, Davis SP, et al: Smoking Characteristics of Adults With Selected Lifetime Mental Illnesses: Results From the 2007 National Health Interview Survey. Am J Public Health. 2010 Dec;100(12):2464–72.

4. Brown S, Kim M, Mitchell C, et al: Twenty five year mortality of a community cohort with schizophrenia. Br J Psychiatry. 2010 Feb;196(2):116–21.

5. Anthenelli RM, Benowitz NL, West R, et al: Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016 Jun 18;387(10037):2507–20.

6. Evins AE, Benowitz NL, West R, et al: Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers With Psychotic, Anxiety, and Mood Disorders in the EAGLES Trial. J Clin Psychopharmacol. 2019;39(2):108–16.

7. Tsoi DT, Porwal M, Webster AC: Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD007253.

8. White SA, Stone E, Murphy KA, et al: Smoking Cessation Medication Prescribing for Smokers With and Without Mental Illness. Psychiatr Serv. 2023 Apr 1;74(4):332–40.

9. Evins AE, Cather C: Addressing Barriers to Provision of First-Line Pharmacotherapy for Tobacco Use Disorder. Psychiatr Serv. 2023 Apr 1;74(4):429–30.

10. Himelhoch S, Riddle J, Goldman HH: Barriers to Implementing Evidence-Based Smoking Cessation Practices in Nine Community Mental Health Sites. PS. 2014 Jan;65(1):75–80.

11. Schnoll RA, Leone FT, Quinn MH, et al: A randomized clinical trial testing two implementation strategies to promote the treatment of tobacco dependence in community mental healthcare. Drug Alcohol Depend. 2023 Jun 1;247:109873.

12. Prochaska JJ: Failure to treat tobacco use in mental health and addiction treatment settings: a form of harm reduction? Drug Alcohol Depend. 2010 Aug 1;110(3):177–82.

13. Grand RBG, Hwang S, Han J, et al: Short-Term Naturalistic Treatment Outcomes in Cigarette Smokers with Substance Abuse and/or Mental Illness. J Clin Psychiatry. 2007 Jun;68(6):892–981.

14. Jester DJ, Thomas ML, Sturm ET, et al:. Review of Major Social Determinants of Health in Schizophrenia-Spectrum Psychotic Disorders: I. Clinical Outcomes. Schizophrenia Bulletin. 2023 Jul 1;49(4):837–50.

15. Trainor K, Leavey G: Barriers and Facilitators to Smoking Cessation Among People With Severe Mental Illness: A Critical Appraisal of Qualitative Studies. Nicotine Tob Res. 2017 Jan;19(1):14–23.

16. American Public Health Association: Support for Community Health Workers to Increase Health Access and to Reduce Health Inequities [Internet]. 2009 [cited 2023 Oct 8]. Available from: https://www.apha.org/policies-and-advocacy/public-health-policy-statements/policy-database/2014/07/09/14/19/support-for-community-health-workers-to-increase-health-access-and-to-reduce-health-inequities

17. Rosenthal EL, Brownstein JN, Rush CH, et al: Community health workers: part of the solution. Health Aff (Millwood). 2010 Jul;29(7):1338–42.

18. Viswanathan M, Kraschnewski JL, Nishikawa B, et al: Outcomes and Costs of Community Health Worker Interventions: A Systematic Review. Medical Care. 2010;48(9):792–808.

19. Evins AE, Cather C, Maravic MC, et al: A Pragmatic Cluster-Randomized Trial of Provider Education and Community Health Worker Support for Tobacco Cessation. Psychiatr Serv. 2023 Apr 1;74(4):365–73.

20. Saunders RP, Evans MH, Joshi P: Developing a process-evaluation plan for assessing health promotion program implementation: a how-to guide. Health Promot Pract. 2005 Apr;6(2):134–47.

21. Massachussetts Department of Public Health, Bureau of Health Professions Licensure, Board of Certification of Community Health Workers: Core Competencies for Community Health Workers [Internet]. 2014 [cited 2023 Dec 9]. Available from: https://www.mass.gov/info-details/core-competencies-for-community-health-workers

22. Pbert L, Ockene JK, Ewy BM, et al: Development of a state wide tobacco treatment specialist training and certification programme for Massachusetts. Tob Control. 2000 Dec;9(4):372–81.

23. Benowitz NL, Bernert JT, Foulds J, et al: Biochemical Verification of Tobacco Use and Abstinence: 2019 Update. Nicotine Tob Res. 2020 Jun 12;22(7):1086–97.

24. Collett D: Modelling Binary Data, Second Edition. CRC Press; 2002. 406 p.

25. R Core Team: R: A language and environment for statistical computing. [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2022 [cited 2023 Oct 13]. Available from: https://www.R-project.org/

26. van Buuren S, Groothuis-Oudshoorn K: mice: Multivariate Imputation by Chained Equations in R. Journal of Statistical Software. 2011;45(3):1–67.

27. O' Connor C, Joffe H: Intercoder Reliability in Qualitative Research: Debates and Practical Guidelines. International Journal of Qualitative Methods [Internet]. 2020 Jan 22 [cited 2023 Oct 8];19. Available from: https://journals.sagepub.com/doi/full/10.1177/1609406919899220

28. Damschroder LJ, Aron DC, Keith RE, et al: Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009 Aug 7;4:50.

29. Breimaier HE, Heckemann B, Halfens RJG, et al: The Consolidated Framework for Implementation Research (CFIR): a useful theoretical framework for guiding and evaluating a guideline implementation process in a hospital-based nursing practice. BMC Nursing. 2015 Aug 12;14(1):43.

30. Cohen J: Things I have learned (so far). American Psychologist. 1990;45(12):1304–12.

31. Campbell JL, Quincy C, Osserman J, et al: Coding In-depth Semistructured Interviews: Problems of Unitization and Intercoder Reliability and Agreement. Sociological Methods & Research. 2013 Aug 1;42(3):294–320.

32. QSR International: NVivo [Internet]. Lumivero; 2017 [cited 2023 Oct 13]. Available from: https://lumivero.com/products/nvivo/

33. National Institute on Drug Abuse: Heaviness of Smoking Index. [Internet]. National Institute on Drug Abuse (NIDA) Data Share Website. [cited 2024 Jan 17]. Available from: https://datashare.nida.nih.gov/instrument/heaviness-of-smoking-index

34. Evins AE, Cather C, Pratt SA, et al: Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA. 2014 Jan 8;311(2):145–54.

35. Evins AE, Hoeppner SS, Schoenfeld DA, et al: Maintenance pharmacotherapy normalizes the relapse curve in recently abstinent tobacco smokers with schizophrenia and bipolar disorder. Schizophrenia Research. 2017 May 1;183:124–9.

36. Daumit GL, Evins AE, Cather C, et al: Effect of a Tobacco Cessation Intervention Incorporating Weight Management for Adults With Serious Mental Illness: A Randomized Clinical Trial. JAMA Psychiatry. 2023 Jun 28;e231691.

37. Hall SM, Tsoh JY, Prochaska JJ, et al: Treatment for cigarette smoking among depressed mental health outpatients: a randomized clinical trial. Am J Public Health. 2006 Oct;96(10):1808–14.

38. Richter KP, Ellerbeck EF: It's time to change the default for tobacco treatment. Addiction. 2015 Mar;110(3):381–6.

39. Barua RS, Rigotti NA, Benowitz NL, et al: 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. Journal of the American College of Cardiology. 2018 Dec 25;72(25):3332–65.

40. Vaughan EM, Hyman DJ, Naik AD, et al: A Telehealth-supported, Integrated care with CHWs, and MEdication-access (TIME) Program for Diabetes Improves HbA1c: a Randomized Clinical Trial. J GEN INTERN MED. 2021 Feb 1;36(2):455–63.

41. Guo YQ, Chen Y, Dabbs AD, et al: The Effectiveness of Smartphone App–Based Interventions for Assisting Smoking Cessation: Systematic Review and Meta-analysis. J Med Internet Res. 2023 Apr 20;25:e43242.

42. Allen JK, Dennison-Himmelfarb CR, Szanton SL, et al: Community Outreach and Cardiovascular Health (COACH) Trial: a randomized, controlled trial of nurse practitioner/community health worker cardiovascular disease risk reduction in urban community health centers. Circ Cardiovasc Qual Outcomes. 2011 Nov 1;4(6):595–602.

43. Kangovi S, Mitra N, Norton L, et al: Effect of Community Health Worker Support on Clinical Outcomes of Low-Income Patients Across Primary Care Facilities: A Randomized Clinical Trial. JAMA Internal Medicine. 2018 Dec 1;178(12):1635–43.

44. De Hert M, Cohen D, Bobes J, et al: Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011 Jun;10(2):138–51.

45. Balcazar H, Rosenthal EL, Brownstein JN, et al: Community Health Workers Can Be a Public Health Force for Change in the United States: Three Actions for a New Paradigm. Am J Public Health. 2011 Dec;101(12):2199–203.

46. Ingram M, Reinschmidt KM, Schachter KA, et al: Establishing a professional profile of community health workers: results from a national study of roles, activities and training. J Community Health. 2012 Apr;37(2):529–37.

47. U.S. Government Publishing Office: Patient Protection and Affordable Care Act [Internet]. 124 Stat. 119, 124 Stat. 119 2010 p. 119–1024. Available from: https://www.govinfo.gov/content/pkg/PLAW-111publ148/pdf/PLAW-111publ148.pdf

48. Rosenbaum S: The Patient Protection and Affordable Care Act: Implications for Public Health Policy and Practice. Public Health Rep. 2011;126(1):130–5.

49. Voils CI, Chang Y, Crandell J, et al: Informing the Dosing of Interventions in Randomized Trials. Contemp Clin Trials. 2012 Nov;33(6):1225–30.

50. Freedman D, Diaconis P: On the histogram as a density estimator:L2 theory. Z Wahrscheinlichkeitstheorie verw Gebiete. 1981 Dec 1;57(4):453–76.

Figure 1: Observed and predicted dose-response

Caption for Figure 1:

Plot of observed response (y-axis) by dose (binned over fixed intervals; x-axis) for each dose-response pair. Each column corresponds to an engagement variable; each row corresponds to a smoking cessation outcome variable. Observed percentage response and 95% confidence intervals (CI) based on a beta-binomial model were calculated over bin sizes determined by the Freedman-Diaconis algorithm [50]. Model predictions and 95% prediction intervals (PI) from a logistic regression model were overlaid. Models have good fit to the observed data, with most binned responses falling within 95% PI. Histograms presenting the observed data distribution from participants are shown at the top of each figure panel for each engagement variable.

Table 1: Summary of dose analysis by engagement variable and smoking cessation treatment outcome variable (N=196)

Outcome	Engagement variable	Test statistics			Expected response with no Intervention	Thresholds for significant improvement		Expected responses at at min and max thresholds		Received ≥ min threshold		Received ≥ max threshold	
			95% CI										
		OR	LL	UL	%	Min	Max	Min	Max	N	%	N	%
Year 2 Tobacco Abstinence	CHW visits	1.85*	1.29	2.66	7.7	30	65	14.0	25.9	71	36	26	13
	CHW visit duration [a]	1.51*	1.00	2.28	7.0	29	34	15.1	16.8	92	47	58	30
	Smoking cessation groups	1.85*	1.33	2.58	9.7	20	57	15.4	33.5	50	26	14	7
	CHW-attended PCP visits [b]	1.05	0.72	1.52	14.7	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Initiated TUD pharmacotherapy	CHW visits	4.03*	2.53	6.44	25.9	9	79	35.8	94.6	129	66	13	7
	CHW visit duration	1.88*	1.36	2.59	25.7	15	49	40.7	75.7	163	83	10	5
	Smoking cessation groups	3.32*	1.97	5.61	39.9	7	61	48.7	94.3	72	37	13	7
	CHW-attended PCP visits	5.64*	2.67	11.91	39.0	1	9	48.1	99.6	75	38	6	3
Initiated varenicline	CHW visits	2.84*	1.98	4.08	14.8	14	81	22.5	78.1	117	60	12	6
	CHW visit duration [d]	0.72*	0.54	0.95	3.2	12	75	14.6	20.3	167	85	N/A	N/A
	Smoking cessation groups	2.09*	1.50	2.92	24.8	12	62	32.8	71.2	61	31	13	7
	CHW-attended PCP visits	2.97*	1.85	4.77	23.4	1	9	31.2	93.9	75	38	6	3

Note. OR: Odds ratio per one standard deviation increase in engagement variable units; CI: Confidence interval; LL: Lower limit; UL: Upper limit; N: Number of participants; CHW: community health worker; TUD: tobacco use disorder; PCP: primary care physician. * $p < .05$.

[a] Limits of prediction intervals for lowest and highest predicted response overlap.

[b] No significant dose-response relationship.

[c] Odds ratio reported for significant quadratic trend for dose-response relationship. Linear OR: 2.37 [1.51, 3.74], $p < .001$

Table 2: Characteristics of interviewed study participants (N=16)

Measure	M/%	SD/N
Demographic characteristics at baseline		
Age (years)	49.5	11.2
Sex (female)	29.4	5
Race		
American Indian or Alaskan Native [a]	0	0
Asian [a]	5.9	1
Black or African American	52.9	9
Hispanic or Latino	23.5	4
Multiracial	0	0
White	17.6	3
Supervised housing	35.3	6
SF-1 [b]	2.9	1.0
Expired CO (ppm) [c]	22.0	20.3
HIS [d]	2.8	1.5
Tobacco products per day	11.3	7.4
Cigarettes (daily use)	88.2	15
Little cigars (daily use)	47.1	8
Hand-rolled cigarettes (daily use)	5.9	1
E-cigarettes (daily use)	0	0
Physician recommendation to quit smoking	58.8	10
Prior year prescribed medication to aid cessation	41.2	7
Cardiovascular/respiratory illness	41.2	7
Other smoking related illness [e]	35.3	6
Treatment and engagement outcomes over two years		
Year 2 tobacco abstinence	17.6	3
Initiated TUD pharmacotherapy	76.5	13
Initiated varenicline	52.9	9
Quantity of CHW visits	40.8	32.1
Average duration of CHW visits	31.5	11.6
Quantity of smoking cessation groups	27.8	31.9
Quantity of CHW-attended PCP visits	2.0	4.0

Note. M: Mean; SD: Standard deviation; N: Number of participants; TUD: tobacco use disorder; CHW: community health worker; PCP: primary care physician.

[a.] Insufficient cell count (≤4 participants) for analyses

[b.] SF-1 is single-item self-report of overall health. Possible scores range from 1 to 5, corresponding to perceived health being poor, fair, good, very good, or excellent.

[c.] Expired air carbon monoxide (CO) is a measure of current smoking; mean CO reported here is consistent with smoking approximately 1 pack per day. Abstinence was defined as ≤ 5 parts per million (ppm) of CO.

[d.] Possible scores on the Heaviness of Smoking Index (HSI) range from 0 to 6; scores of 0–2 indicate low severity of nicotine dependence, 3 and 4 indicate moderate dependence, and 5 and 6 indicate severe dependence.

[e.] Includes diabetes, cancer, pneumonia, tuberculosis, cataracts, glaucoma, and retinal disease

Table 3: CHW, PCP, and study participants' perceived barriers and facilitators to engagement with and implementation of CHW intervention.

CFIR Domain and Construct	Barriers and Facilitators to Engagement and Implementation of CHW Intervention	Illustrative Quotes	Recommendations for Future Implementation
Innovation Characteristics; Individuals' Role and Characteristics	**CHW role in facilitating TUD treatment engagement and health behavior change**		
	CHWs provided behavioral health coaching, goal accountability, and reinforced skills for smoking cessation, through: - Alliance building - Health promotion and psychoeducation - Motivational interviewing - Use of carbon monoxide monitor - Behavioral change strategies	***Alliance building through engagement with health goals*** "When I first started working with him, he was very reluctant to quit smoking. His mindset was, "I'll listen but nothing you say is ever going to get me to quit." So, I started talking about his health goals and things he was concerned about. He would end up mentioning smoking and open up more." – CHW "I took him to the grocery store to learn how to eat healthier. So he reinvested in taking care of himself … it was part of the relationship." – CHW ***CHW supported tobacco cessation goal accountability*** "The carbon monoxide monitor was good to have with us. If you did it at the beginning of your meeting and you did it after an hour-long appointment, it went down. That was instant gratification." – CHW "[My CHW is] great, she understands [me]. If I smoked when I wasn't supposed to she wouldn't be mean about it, just gave me more support and made sure that I can [get to my] goal." – Participant ***CHWs reinforced skills from smoking cessation groups*** "Getting to know my clients within the group setting and working with them individually as well has helped to kind of personalize the way that I produce the information and present it." – CHW	• Extended duration of CHW engagement can help build alliance and motivation among participants who are less ready to quit • Use low-burden tools (e.g., carbon monoxide monitor) to aid measurement-based care and treatment engagement • Extend smoking cessation group's curriculum with personalized, in person practice during community-based CHW visits
	CHWs helped to overcome participants' barriers to treatment access and adherence	***CHWs flexibly met in participants' home or community environment*** "The community-based model is effective. I can't imagine anyone in my entire caseload coming to a scheduled meeting. I think us going to them was absolutely critical." – CHW "You're in someone's home a lot of the time. Not that boundaries are blurred, but you do things so differently than you would do in the traditional outpatient setting…acknowledging that this is their space, what they want to do." – CHW	• Emphasize CHW's role in overcoming participants' adverse social determinants of health and barriers to care in training and integrated team orientation • Reduce transportation barriers with greater use of phone communication with CHWs; telehealth; and subsidized transportation services

CFIR Domain and Construct	Barriers and Facilitators to Engagement and Implementation of CHW Intervention	Illustrative Quotes	Recommendations for Future Implementation
		CHWs organized transportation and scheduling to ensure participant attendance of primary care appointments and smoking cessation groups "It's kind of a bummer [the CHW is] gone [with the end of the trial] because she helped get him to the appointment. I've only seen him once alone since. That's half the battle, just getting in the room." – PCP "[What was most effective] was my consistency in setting up PCP appointments, setting up rides, helping them get to group knowing that they could call me. Setting up consistent appointments with me too was good for them and helped build their confidence in terms of their quit success." – CHW "Every group time, she would come and pick us up so there was no barrier getting there. And if she didn't come pick us up, we got a car here that would pick us." – Participant ***CHWs navigated insurance limitations affecting prescription access*** "We did some stuff with his MassHealth insurance. There were a couple times where his income had changed, so that had lapsed, so I helped reapply for that." – CHW	
Inner and Outer Setting	**Care coordination with primary care other providers**		
Teaming	CHWs experienced mixed success in collaborating and coordinating care with PCPs	***Positive experiences and attitudes associated with CHW role as patient advocate and care coordinator with PCP*** "These patients need an advocate, and I oftentimes don't have a great idea of what's going on in their day-to-day life, but a CHW tends to have a better idea of what will help with medication compliance or actually showing up to visits…which, especially patients with severe mental illness, they're not always able to communicate that in a way that providers really understand or know what they're asking for, or they're sometimes afraid to." – PCP "[With the CHW], I was confident that information was going to stick and be relayed appropriately to the group home or the patient. It takes a village to really help in coordinating patients' care." – PCP "We do role-playing practice. We're in the car right before, and we're like, "What are we going to say to Dr. C? What do you want to do?"" – CHW	• Include education about the CHW role in provider education to promote effective collaboration between the PCPs and CHWs • Specify strategies for coordinating care with PCPs in CHW training and supervision

CFIR Domain and Construct	Barriers and Facilitators to Engagement and Implementation of CHW Intervention	Illustrative Quotes	Recommendations for Future Implementation
		Negative experiences and attitudes towards CHW-PCP collaboration (should this be worded in a way that's parallel to the above?) "I've had PCPs throw the packet back at my face. They're just not receptive. All of us got a lot of push back. "You're not a medical professional. Don't tell me how to do my job." With PCPs that were a little bit more closed-minded, there wasn't a ton we could do." – CHW "[In one example], the CHW was pushing the smoking cessation treatment. It comes from a good place, but I think it creates a weird dynamic… like I'm not doing what's best for the patient, or that they know better for their treatment." – PCP	
Partnerships and Connections	Other care providers' mixed attitudes towards and limited knowledge of CHW role	***Positive experiences of group home staff who supported participants' smoking cessation goals*** "Some group home staff were so involved with the CHWs, and they were helping us get in touch with the client and making sure the clients were taking their meds." – CHW ***CHWs faced challenges integrating and coordinating care with external care providers*** "There're so many agencies interconnected, but sometimes I didn't feel connected to everything. They know us but are still unclear about what we do. It did feel like us against them, which I don't think was the plan." – CHW	• Integrate CHWs as a health-focused provider in the psychiatric rehabilitation care system, with appropriate training, educational resources, and promote awareness about their role in supporting participants' behavioral health goals (i.e., coaching, care coordination, and system navigation)
Implementation Process	**Importance of CHW training and supervision**		
	CHWs received adequate training and supervision and felt competent and effective in their role	***Positive experiences and strengths of CHW training and supervision*** "The training really helped me to be confident. I was very nervous before the intervention started. But we had such long-term and concrete training that I found helpful, such as the tobacco treatment training and motivational interviewing…I [also] couldn't have done this job without the supervision and clinical support we had from our supervisors and other CHWs. We could get different perspectives from supervision and develop well-rounded solutions or different approaches to clients." – CHW ***Areas of improvement for CHW training and supervision*** "As far as content, we could have had more trauma-informed stuff, and then kind of just how [the Department of Mental Health] works. It's a complicated system that I don't think we touched upon enough." – CHW "The reality of what it's like being like a very poor, very sick Black man in a group home is different. There's a diverse population of clients.	• Retain CHW training and supervision structure to develop CHW competency and self-efficacy • Improve CHW training by preparing CHWs for community-based involvement, responsibilities, and challenges of working with SMI population • CHW-recommended topics for future training include: knowledge about public and community system of care, working with people with adverse social determinants of health, and cultural

CFIR Domain and Construct	Barriers and Facilitators to Engagement and Implementation of CHW Intervention	Illustrative Quotes	Recommendations for Future Implementation
		And I think being more cognizant of that and what works for some doesn't work for others." – CHW	competency/humility • Recruitment of CHWs can consider selecting individuals from the same community/neighborhoods, and from diverse/similar cultural backgrounds to participants.

Note. CFIR: Consolidated Framework for Implementation Research; CHW: community health worker; PCP: primary care physician; TUD: tobacco use disorder.

Figure 1: Observed and predicted dose-response



ONLINE SUPPLEMENT 1

Detailed Qualitative Analysis Methods

We include this supplement to provide detailed and transparent reporting of qualitative methods and analytic procedures. In the qualitative phase, we identified barriers and facilitators to engagement with and implementation of the community health worker (CHW)-supported tobacco cessation intervention from CHW, patient participant, and primary care physicians (PCP) who completed the two-year intervention.

Thematic analysis was chosen as the overarching qualitative analysis method as it is a systematic and flexible approach that aligns with the mixed methods objectives to complement the quantitative results, allowing for the deductive coding frame to be derived from theory-driven quantitative variables while still allowing for themes to emerge inductively from the data.[1,2] Specifically, we undertook an inter-coder reliability (ICR) approach to thematic analysis[3] to prioritize reliability of data coding, where themes were identified based on the agreement among multiple coders. An ICR procedure does not conflict with the interpretative goals of qualitative research; instead, it improves the systematicity and transparency of the coding process and demonstrates that a team of researchers working within a shared conceptual framework can arrive at a consensual understanding of the data. We analyzed transcripts from each stakeholder group separately (i.e., CHW, participant, PCP) using the ICR procedure illustrated in Figure A. Qualitative analysis was managed using NVivo 12 for Mac.

In Stage 1, CF developed an initial, deductive coding frame based on higher-order domains and sub-constructs from the Consolidated Framework for Implementation Research (CFIR),[4] including: intervention characteristics of provider education, CHW support, and smoking cessation groups; outer setting; inner setting of primary care centers; and individual characteristics of CHWs and patient participants. *Intervention characteristics* included constructs related to perceived evidence strength and quality of the intervention, perceived difficulty of implementing the intervention, and perceived flexibility of the intervention to be adapted. *Outer setting* referred to external policies, incentives, other care entities, and structural barriers and facilitators that could influence the implementation of the intervention. *Inner setting* referred to characteristics and implementation readiness of primary care centers and primary care physicians, including structural characteristics, capacity and resources, values and behavioral norms of the organization, openness to and support of the intervention, and capacity of change. *Characteristics of CHWs* consisted of CHW attitudes towards the intervention, and beliefs about one's own capabilities related to the implementation of the intervention. *Characteristics of patient participants* consisted of participants attitudes towards the intervention and other characteristics that may influence implementation of the intervention (e.g., individual stage of change, cognitive impairments, severity of illness). We included two higher-order categories related to the qualitative research question to assess successful CHW-support strategies and specific recommendations for future implementation.

Team members trained in qualitative analysis and ICR (CF, LN, AR) independently coded transcripts by segmenting and labeling the text according to specific points that were raised. Themes were inductively developed by aggregating similar codes together, confirmed by team discussion and consensus, and then mapped onto the CFIR deductive frame. Constructs that did not have any relevant codes were removed. The output was an initial codebook that comprehensively, exhaustively, and parsimoniously captured codes across all transcripts from a stakeholder group, and organized into higher-order code categories based on the CFIR.[5]

In Stage 2, a stepwise method of ICR assessment was conducted where three to four randomly selected transcripts per stakeholder group (25% of sample) were double-coded to improve the reliability and transparency of the coding frame such that those using it would

consistently apply the same codes to the same excerpts.[3] Stepwise rounds of ICR testing were implemented until satisfactory reliability was achieved, with the coding frame refined after each round.[6,7] The second coder received an uncoded file that highlights the segmented data units, but not their associated codes. The second coder then used the initial codebook to independently code the data units that were visible on the cleaned file. The first and second coder's codes were compared, and reliability was calculated based on the Cohen's kappa coefficient[8] computed by NVivo 12, a statistical measure of ICR that corrects for agreement that could occur through chance, for the overall coding frame as well as individual codes. After comparison of one double-coded transcript, discussion meetings were held to expose similarities and differences in ways of applying codes and come to consensus in coding.[6,9] Codes were more carefully described and operationalized during discussions between team members to produce a revised codebook for the next round of ICR until overall kappa coefficient of $\geq$ 0.75 for acceptable reliability was reached.[10] In our study, we reached satisfactory reliability typically by two rounds of ICR for all three stakeholder groups.

In Stage 3, the finalized coding frame for each stakeholder group was applied to the remaining single-coded transcripts. We reviewed and synthesized all codes across stakeholder groups to identify major salient themes with consideration of lesser endorsed codes that were still relevant and important to informing future implementation of the CHW intervention. We reported our qualitative methods and results based on the Standards for Reporting Qualitative Research (SRQR) guideline to ensure transparency and rigor.[11] Trustworthiness of our findings was strengthened by inter-coder reliability; rich and thick description of the cases with illustrative quotes reported as evidence; reviewing and reporting lesser endorsed and contrary evidence; subject matter expert external audit (AEE, AT, CC).

ONLINE SUPPLEMENT 1

Figure A. *Inter-coder reliability procedure.*



ONLINE SUPPLEMENT 1

References for Online Supplement 1

1. Fereday J, Muir-Cochrane E. Demonstrating Rigor Using Thematic Analysis: A Hybrid Approach of Inductive and Deductive Coding and Theme Development. International Journal of Qualitative Methods. SAGE Publications Inc; 2006 Mar 1;5(1):80–92.

2. Joffe H. Thematic Analysis. In: Harper D, Thompson AR, editors. Qualitative Research Methods in Mental Health and Psychotherapy: A Guide for Students and Practitioners. Chichester: John Wiley & Sons, Ltd; 2011.

3. O'Connor C, Joffe H. Intercoder Reliability in Qualitative Research: Debates and Practical Guidelines. International Journal of Qualitative Methods. SAGE Publications Inc; 2020 Jan 1;19:1609406919899220.

4. Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009 Aug 7;4:50. PMCID: PMC2736161

5. Malterud K. Qualitative research: standards, challenges, and guidelines. Lancet. 2001 Aug 11;358(9280):483–488. PMID: 11513933

6. Campbell JL, Quincy C, Osserman J, et al. Coding In-depth Semistructured Interviews: Problems of Unitization and Intercoder Reliability and Agreement. Sociological Methods & Research. SAGE Publications Inc; 2013 Aug 1;42(3):294–320.

7. Hruschka DJ, Schwartz D, St.John DC, et al. Reliability in Coding Open-Ended Data: Lessons Learned from HIV Behavioral Research. Field Methods. SAGE Publications Inc; 2004 Aug 1;16(3):307–331.

8. Cohen J. Things I have learned (so far). American Psychologist. US: American Psychological Association; 1990;45(12):1304–1312.

9. Miles MB, Huberman AM, Saldana J. Qualitative Data Analysis: A Methods Sourcebook. Third Edition. SAGE Publications Ltd (CA). SAGE Publications; 2014.

10. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977 Mar;33(1):159–174. PMID: 843571

11. O'Brien BC, Harris IB, Beckman TJ, et al. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014 Sep;89(9):1245–1251. PMID: 24979285

ONLINE SUPPLEMENT 2

Online Supplement Table 1: Baseline characteristics of study participants by enrollment and retention

Measure	Consented to CHW support and retained (N=196)		Did not consent to CHW support or dropped out before Year 1 (N=137)		*p* value
	M/%	SD/N	M/%	SD/N	
Age (years)	48.6	12.1	45.9	13.3	0.244
Sex (female)	29.6	58	32.8	45	0.813
Race					
American Indian or Alaskan Native [a]	1	2	0	0	
Asian [a]	2	4	4.4	6	
Black or African American	38.8	76	26.3	36	0.156
Hispanic or Latino	17.3	34	19	26	0.813
Multiracial	3.1	6	3.6	5	0.813
White	36.7	72	45.3	62	0.350
Supervised housing	51	100	32.1	44	0.012
SF-1 [b]	3.1	1.1	3	1.1	0.813
Expired CO (ppm) [c]	22.8	18.6	22.6	18.6	0.916
HSI [d]	2.7	1.5	2.8	1.7	0.813
Tobacco products per day	14	9.2	15.5	10.2	0.350
Cigarettes (daily use)	81.6	160	79.6	109	0.813
Little cigars (daily use)	34.7	68	32.8	45	0.813
Hand-rolled cigarettes (daily use)	7.7	15	8.8	12	0.813
E-cigarettes (daily use)	0	0	0.7	1	
Physician recommendation to quit smoking	64.3	126	56.2	77	0.350
Prior year prescribed medication to aid cessation	33.2	65	21.9	30	0.156
Cardiovascular/respiratory illness	41.3	81	44.5	61	0.813
Other smoking related illness [e]	27	53	34.3	47	0.350

Note. Participants who were retained completed Year 1 and 2 assessments. N=43 in this group had missing data for tobacco abstinence outcomes, and had data imputed via predictive mean matching using Year 1 abstinence outcomes and baseline characteristics. More participants who were retained in the CHW intervention lived in supervised housing. M: Mean; SD: Standard deviation; N: Number of participants.

[a.] Insufficient cell count (≤4 participants) for analyses

[b.] SF-1 is single-item self-report of overall health. Possible scores range from 1 to 5, corresponding to perceived health being poor, fair, good, very good, or excellent.

[c.] Expired air carbon monoxide (CO) is a measure of current smoking; mean CO reported here is consistent with smoking approximately 1 pack per day. Abstinence was defined as ≤ 5 parts per million (ppm) of CO.

[d.] Possible scores on the Heaviness of Smoking Index (HSI) range from 0 to 6; scores of 0–2 indicate low severity of nicotine dependence, 3 and 4 indicate moderate dependence, and 5 and 6 indicate severe dependence.

[e.] Includes diabetes, cancer, pneumonia, tuberculosis, cataracts, glaucoma, and retinal disease.

ONLINE SUPPLEMENT 3

Barriers and Facilitators to Engagement in Provider Education and Smoking Cessation Groups

In the parent clinical trial's intervention group, primary care clinics received a one-time, clinician-delivered provider education (PE) on safety, efficacy, and importance of tobacco cessation pharmacotherapy; study participants who received care in PE-assigned clinics and were randomized to the intervention group also received up to two years of community health worker (CHW) support and weekly group counseling sessions on smoking cessation. Our primary focus was understanding facilitators and barriers to CHW engagement, but we were also interested in understanding the acceptability, perceived effectiveness, and factors influencing implementation for provider education (PE) and smoking cessation groups. In this supplement, we summarize our understanding of these factors based on interviews with CHWs, primary care providers (PCPs), and study participants. Barriers and facilitators to each of these components of the intervention are outlined in the Online Supplement Table below, which furnishes illustrative quotes associated with each barrier and facilitator as well as implementation recommendations for future iterations of these interventions.

Provider Education

While a majority of CHWs and PCPs experienced PE to be useful in promoting PCPs' receptiveness towards prescribing first-line cessation medications to individuals with serious mental illness, some CHWs also described their challenging experiences with PCPs who, despite having received PE, continued to be hesitant about prescribing varenicline due to their perceptions of associated psychiatric risks. Several of the interviewed PCPs did in fact report reluctance to prescribe varenicline due to concerns about psychiatric side effects.

Having an implementation champion in the primary care setting was identified as a facilitator of PCPs' engagement with PE. For example, PCPs noted being more likely to prioritize smoking cessation and change their TUD prescribing practices when they received this message, or observed a change in practice, from the chief of their service. Several PCPs identified time constraints as the major barrier to PE engagement and implementation. They recommended greater incentives and incorporation of PE into their regular workflow as ways to increase PE attendance and maximize the implementation of best practice guidelines for tobacco cessation.

Smoking Cessation Groups

CHWs and participants found smoking cessation groups effective in providing goal accountability and positive reinforcement for cessation goals through several strategies: psychoeducation about smoking and health consequences; teaching behavioral change skills; and providing social support and peer accountability, especially through hearing successful quit stories and effective strategies used by group members and guest speakers with lived experience.

Online Supplement Table 2. CHW, PCP, and participants' perceived barriers and facilitators to engagement with and implementation of PE and smoking cessation groups.

CFIR Domain and Construct	Barriers and Facilitators to Intervention Engagement and Implementation	Illustrative Quotes	Recommendations for Future Implementation
Innovation Characteristics; Inner Setting	**Acceptability, perceived effectiveness, and implementation of Provider Education (PE) in primary care**		
Intervention characteristics; compatibility with normative practices of the organization	Mixed effectiveness of PE in improving PCPs' willingness to prescribe TUD pharmacotherapy	***PCPs' improved receptiveness and willingness to prescribe TUD pharmacotherapy after PE*** "After the education that we got about the efficacy of the Chantix for psychiatrically impaired people, I started applying it pretty actively. Before that, I had no reason to because [I thought] it increased depression and had other psychiatric side effects. If I had somebody who was on it, or who had asked me for it, I would always defer to asking the psychiatrist or the psychopharmacologist about their opinion." – PCP "The biggest change was making sure that I was offering medication regularly to help people quit. [I felt] much more comfortable to just be able to say, "More people do better with this, and this is an option for you." I wrote more prescriptions." – PCP ***PCPs' ambivalence towards prescribing varenicline*** "I'm still very leery of decompensation. I just saw a patient yesterday and he's kind of gone back to smoking and he's got depression. He's on about five or six psychiatric meds. And so obviously, Chantix we both agreed is not something we can start." – PCP "My client was advocating for themselves, I was advocating for them, we were really trying and [the PCP] would not budge on the Chantix thing, even after I pointed out that the black box warning label was removed. It's disheartening because the client and I had just built trust and gotten over any misconceptions he has about medication." – CHW	• Emphasize efficacy of CHW+PE intervention in improving rates of cessation medication prescription and smoking cessation in future PE
Mission alignment and incentive systems	Implementation champion prioritized smoking cessation and PE	"The chief of medicine said, "I would never have thought to start Chantix before someone's ready to quit in order to sort of improve readiness to quit." Hearing him say what was eye-opening to him as an experienced clinician, that made a big impact on me." – PCP	• Identify and partner with implementation champions in primary care settings to improve uptake and adoption of CHW+PE intervention as standard of care

ONLINE SUPPLEMENT 3

CFIR Domain and Construct	Barriers and Facilitators to Intervention Engagement and Implementation	Illustrative Quotes	Recommendations for Future Implementation
Available resources	Time constraints limited PE attendance	"There would have to be an incentive to make time and make it worthwhile to the providers to be present [for PE]. That's become more difficult because of all our demands." – PCP	• To improve attendance, PE can be delivered: virtually; via asynchronous digital learning platforms; as part of protected time for continuing education; as part of team meetings with feedback on physician prescribing and identified list of patients who will benefit from pharmacotherapy
Innovation Characteristics	**Acceptability and perceived effectiveness of Smoking Cessation (SC) Groups**		
Intervention characteristics	SC groups provided goal accountability and positive reinforcement for smoking cessation, via: - Psychoeducation and skills building - Peer accountability and support - Motivation from speakers with lived experience	***SC groups built skills and provided motivation and goal accountability for smoking cessation*** "The group taught me how to delay and taught me how to not smoke so much. They helped me with getting lozenges and smoking tools and just having people on my side rooting me on to not smoke" – Participant "I was the very first person in the smoke group to start the Chantix, and when all the clients in the group seen how the Chantix was working for me, they all wanted to talk to their doctors to see if they could get prescribed the Chantix. And everybody who I started that quit smoking group with-- at least 10 of them got on the Chantix and about four or five people ended up quitting for good during that two and half years of that group study." – Participant ***SC groups provided social support*** "One of my favorite parts was seeing how the clients interact with one another, they cheer-lead for each other. They are getting the intervention from the groups, but they [also] build rapport with one another. They want the other clients to get the intervention. They want them to quit and everything."—CHW ***Motivation from guest speakers with lived experience*** "I could see that if a guest speaker came in to talk, they felt more motivated and they felt like they could really trust them with their questions and not feel judged." – CHW	• Enhance patient motivation and engagement in SC groups with successful quit stories from group members and persons with lived experience